Medtronic Reports One Year (ADAPT) Study Results of MiniMed 780G Advanced Hybrid Closed Loop System for Type 1 Diabetes
- The (ADAPT) study evaluating MiniMed 780G advanced hybrid closed loop system vs SoC (multiple daily injections of insulin + intermittently scanned CGM) in adults aged ≥18yrs. with T1D
- The results showed an improvement in clinical outcomes with the MiniMed 780G system; mean HbA1c (8.9% for MDI+isCGM @6mos. vs 7.5% @12mos. switched to AHCL), mean time in range (43.6 % vs 70.7%) while mean HbA1c for AHCL (7.3 % in AHCL @6mos. & 7.4 % remained on AHCL @12mos.)
- The results from 2nd randomized controlled study (CLVer) sponsored by JDRF showed early intensive management, incl. the use of an automated insulin delivery system resulted in a superior time in the range of 78% vs 64% in the SoC @1yr. The results were presented at the ATTD conference & published in JAMA
Ref: PRNewswire | Image: Medtronic
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.